If you haven't heard of Rett syndrome, it's probably because it's very rare. Affecting an estimated one in 12,000 baby girls ...

The field of neuroscience has benefited significantly from the groundbreaking work of dedicated researchers who have ...

Phil and Claire Drinkwater have raised more than £11,000 for charity since the loss of their 'joyful' son Jude ...

Rett syndrome is a neurodevelopmental disorder that primarily affects girls, most of whom have mutations in the transcription regulatory gene MECP2. However, mutations in MECP2 also have been ...

Rare diseases have become an attractive target for pharmaceutical companies both in Australia and internationally with ...

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...

Taysha Gene Therapies' TSHA-102 tackles Rett syndrome’s root cause with its miniMECP2 transgene and scAAV delivery. So far, this is TSHA’s main value driver, and it appears safe and effective ...

Special Report: Neurotech International has inked a deal with a European leader in development and scale up of cannabis-based ...

D. Boral Capital reaffirmed their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL – Free Report) in a report published on Wednesday morning,Benzinga reports. D. Boral Capital currently has a ...

Romi Loffler fears she will be among the hardest hit by East Renfrewshire Council's decision to means-test and charge for ...

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmac ...